Bluebird Bio | BLUE - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Arrowhead Research USD 28.27M 7.85M 2025-12
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09